ARISTOCRAT

TOMORROW'S INNOVATORS IN SCIENCE, TECHNOLOGY, ENGINEERING AND MATH

98978549

Bristol-Myers Squibb Company

EMPLICITI

99424859

BRISTOL-MYERS SQUIBB COMPANY

SPRYCEL

78140234

Bristol-Myers Squibb Company

OPDIVO

86174642

Bristol-Myers Squibb Company

ARISTOCRAT

72140148

MARINE CONSTRUCTION & DESIGN CO.he

ARISTOCRAT

71283674

COOLEY FINISHING COMPANY, THE

ARISTOCRAT

71513296

COOLEY, INCORPORATED

ARISTOCRAT HOTELS

73685771

ARISTOCRAT HOTELS, INC.

IXEMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY

77775355

IXAMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY

77775341

IXAMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY

77760923

IXEMPLE A PHASE III OPEN LABEL, RANDOMIZED, 2 ARM STUDY OF IXABEPILONE ADMINISTERED EVERY 21 DAYS VERSUS PACLITAXEL OR DOXORUBICIN ADMINISTERED EVERY 21 DAYS IN WOMEN WITH ADVANCED ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH CHEMOTHERAPY

77760937